These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34108645)

  • 1. Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.
    Hoffman RM; Mott SL; McDowell BD; Anand ST; Nepple KG
    Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):100-108. PubMed ID: 34108645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of expectant management based on prostate cancer risk and health status: How far are we from a risk-adapted approach?
    Spratte BN; Tan HJ; Zambrano IA; Basak RS; Filson CP; Jacobs BL; Hwang S
    Urol Oncol; 2023 Jul; 41(7):323.e17-323.e25. PubMed ID: 37149430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
    Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
    Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.
    Al Hussein Al Awamlh B; Wu X; Barocas DA; Moses KA; Hoffman RM; Basourakos SP; Lewicki P; Smelser WW; Arenas-Gallo C; Shoag JE
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):395-402. PubMed ID: 35882950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
    Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
    JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study.
    Moschini M; Fossati N; Sood A; Lee JK; Sammon J; Sun M; Pucheril D; Dalela D; Montorsi F; Karnes RJ; Briganti A; Trinh QD; Menon M; Abdollah F
    Eur Urol Focus; 2018 Jan; 4(1):68-74. PubMed ID: 28753764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
    Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
    JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
    Leapman MS; Wang R; Loeb S; Seibert TM; Gaylis FD; Lowentritt B; Brown GA; Chen R; Lin D; Witte J; Cooperberg MR; Catalona WJ; Gross CP; Ma X
    J Urol; 2023 Apr; 209(4):710-718. PubMed ID: 36753746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
    Shavers VL; Brown ML; Potosky AL; Klabunde CN; Davis WW; Moul JW; Fahey A
    J Gen Intern Med; 2004 Feb; 19(2):146-55. PubMed ID: 15009794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence review of active surveillance in men with localized prostate cancer.
    Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
    Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States.
    Al Hussein Al Awamlh B; Ballman KV; Ma X; Hu JC; Shoag JE
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):714-717. PubMed ID: 32661433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
    Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
    J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer.
    Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC
    J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial Disparities in Active Surveillance for Prostate Cancer.
    Krishna S; Fan Y; Jarosek S; Adejoro O; Chamie K; Konety B
    J Urol; 2017 Feb; 197(2):342-349. PubMed ID: 27596691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.